...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Biography of Barry S. Coller
【24h】

Biography of Barry S. Coller

机译：巴里·科勒的传记

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Each year, more than 1.2 million Americans suffer a heart attack, and approximately 700,000 suffer a stroke. Both conditions currently rank in the top three leading causes of death in the United States. Three decades ago, researchers knew little about the role of platelets and their interactions with other proteins in contributing to these adverse health events. However, since the mid-1970s, physician and investigator Barry S. Coller has made great contributions toward understanding the mechanisms behind platelet aggregation and the receptors and ligands involved. Over the course of his career, Coller and his colleagues have contributed to elucidating the receptors for fibrinogen (αIIbβ3; GPIIb/IIIa) and von Willebrand factor (GPIb), which are crucial to the clotting process. Based on these findings, his team developed monoclonal antibodies that bind to these receptors, inhibiting platelet aggregation and thus slowing or stopping the cascade of events that leads to heart attack and stroke. The drug abciximab, developed from one of these antibodies (7E3), has been used to treat more than 2 million patients since its Food and Drug Administration (FDA) approval in 1994.
机译：每年，超过120万美国人心脏病发作，大约70万人中风。目前，这两种情况均是美国死亡的三大主要原因。三十年前，研究人员对血小板的作用及其与其他蛋白质的相互作用在促成这些不良健康事件中所起的作用还知之甚少。但是，自1970年代中期以来，医师和研究人员Barry S. Coller为了解血小板聚集以及相关的受体和配体的机制做出了巨大贡献。在他的职业生涯中，Coller及其同事为阐明对凝血过程至关重要的纤维蛋白原（αIIbβ3; GPIIb / IIIa）和血管性血友病因子（GPIb）受体做出了贡献。基于这些发现，他的团队开发了与这些受体结合的单克隆抗体，从而抑制血小板聚集，从而减缓或终止了导致心脏病发作和中风的一系列事件。自1994年获得美国食品药品监督管理局（FDA）批准以来，由其中一种抗体（7E3）开发的药物abciximab已被用于治疗超过200万患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号